Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2013-06-08
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild FATIGUE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-13 (study day 36.0); relationship: POSSIBLE
mild
assessed
Mild HYPERSOMNIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-13 (study day 36.0); relationship: POSSIBLE
moderate
assessed
Moderate SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-07-31 (study day 54.0); relationship: PROBABLE
Data queries
No data queries.